Stock Research: Ebos

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Ebos

NZSE:EBO NZEBOE0001S6
13
  • Value
    55
  • Growth
    19
  • Safety
    Safety
    37
  • Combined
    19
  • Sentiment
    12
  • 360° View
    360° View
    13
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

EBOS Group Limited is a marketer, wholesaler, and distributor of healthcare, medical, and pharmaceutical products, and animal care brands. It operates in the Healthcare and Animal Care industries and includes brands such as Symbion, ProPharma, and TerryWhite Chemmart. It operates in Australia and New Zealand. In the last fiscal year, the company had a market cap of $4,833 million, profits of $1,089 million, revenue of $8,793 million, and 5200 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 13 (better than 13% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ebos are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four metrics below average for Ebos. The only rank that is above average is the consolidated Safety Rank at 55, which means that the company has a financing structure that is safer than those of 55% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the Value, Growth and Sentiment Ranks are all below average. The consolidated Value Rank has a less desirable rank of 37, which means that the share price of Ebos is on the high side compared with typical size in indicators such as revenues, profits, and invested capital. The consolidated Growth Rank also has a low rank of 19, which implies that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. Finally, the consolidated Sentiment Rank is also low at a rank of 12, which means that professional investors are more pessimistic about the stock than for 88% of alternative investment opportunities. While Safety is strong, it’s not the most critical indicator, so we suggest proceeding with caution if you are considering this stock. ...read more

more
Index
SDG 13
SDG 3
SDG 8
NZSX 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Sep-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 11 16 15
Growth
19 43 3 91
Safety
Safety
55 39 55 55
Sentiment
12 65 62 82
360° View
360° View
13 22 12 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
30 53 34 49
Opinions Change
6 68 21 50
Pro Holdings
n/a 27 82 60
Market Pulse
67 81 76 85
Sentiment
12 65 62 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
37 11 16 15
Growth
19 43 3 91
Safety Safety
55 39 55 55
Combined
19 12 6 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
37 17 23 16
Price vs. Earnings (P/E)
62 51 66 61
Price vs. Book (P/B)
67 14 17 23
Dividend Yield
72 40 48 36
Value
37 11 16 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
55 49 1 61
Profit Growth
48 20 49 31
Capital Growth
10 22 7 87
Stock Returns
21 71 15 87
Growth
19 43 3 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
51 37 48 52
Refinancing
23 10 24 28
Liquidity
66 68 69 62
Safety Safety
55 39 55 55

Similar Stocks

Discover high‑ranked alternatives to Ebos and broaden your portfolio horizons.

Nipro

TSE:8086
Country: Japan
Industry: Health Care Supplies
Size: Large
Full Stock Analysis

Alfresa Holdings

TSE:2784
Country: Japan
Industry: Health Care Distributors
Size: Large
Full Stock Analysis

Suncorp

ASX:SUN
Country: Australia
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

Flight Centre Travel

ASX:FLT
Country: Australia
Industry: Hotels, Resorts & Cruise Lines
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.